KESIMPTA
As listed in the register: KESIMPTA
20 mg · solution
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Ofatumumab
- Made by
- Novartis Pharmaceuticals Canada Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (KESIMPTA). It describes the substance, not this exact product.
The precise mechanism by which ofatumumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes.
Following cell surface binding to B lymphocytes, ofatumumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.
Drug Interaction Studies Ofatumumab does not share a common clearance pathway with chemical drugs that are metabolized by the cytochrome P450 system or other drug-metabolizing enzymes.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-04-01
Safety of the active substance
From the US prescribing label for the same active substance (KESIMPTA). It describes the substance, not this exact product.
- KESIMPTA is contraindicated in patients with: Active HBV infection [see Warnings and Precautions (5.1)].
- History of hypersensitivity to ofatumumab or life-threatening injection-related reaction to KESIMPTA.
- Hypersensitivity reactions have included anaphylaxis and angioedema [see Warnings and Precautions (5.2)].
- Active HBV infection.
The most common adverse reactions occurring in greater than 10% of patients treated with KESIMPTA and more frequently than in patients treated with teriflunomide were upper respiratory tract infections, injection-related reactions (systemic), headache, and injection-site reactions (local).
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Novartis Pharmaceuticals Canada Inc |
|---|---|
| Active substance | Ofatumumab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 20 mg |
| Form | solution |
| Classification | L04AG12 · Cancer treatments and immune-system medicines |
| Route | subcutaneous |
| Dispensing (as stated by the register) | SCHEDULE D · PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02511355 |
| DPD drug code | 100057 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution2 products
20 mg2
20 mg · 2 companies
- Novartis Pharmaceuticals Canada Inc · this page
- Novartis Pharmaceuticals Canada Inc
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.